The risk factors for diabetic peripheral neuropathy: A meta-analysis

Xiuxiu Liu, Yuyan Xu, Miaomiao An, Qibing Zeng, Xiuxiu Liu, Yuyan Xu, Miaomiao An, Qibing Zeng

Abstract

Diabetic peripheral neuropathy (DPN), the most common chronic complication of diabetes, has become an important public health crisis worldwide. Given that DPN is extremely difficult to treat, determining its risk factors and controlling it at an early stage is critical to preventing its serious consequences and the burden of social disease. Current studies suggest that the risk factors for diabetic peripheral neuropathy are the duration of diabetes, age, glycosylated hemoglobin A1c (HbA1c), diabetic retinopathy (DR), smoking, and body mass Index (BMI). However, most of the aforementioned studies are cross-sectional, and the sample sizes are very limited, so the strength of causal reasoning is relatively low. The current study systematically evaluated DPN's influencing factors in patients with type 2 diabetes using evidence-based medicine. Overall, 16 included studies (14 cross-sectional studies and 2 case-control studies including 12,116 cases) that conformed to the present criteria were included in the final analysis. The results suggested that the duration of diabetes (MD 2.5, 95% CI 1.71~3.29), age (MD 4.00, 95% CI 3.05~4.95), HbA1c (MD 0.48, 95% CI 0.33~0.64), and DR (OR 2.34, 95% CI 1.74~3.16) are associated with significantly increased risks of DPN among diabetic patients, while BMI, smoking, total triglyceride (TG), and total cholesterol (TC) did not indicate any risks of increasing DPN. The findings provide a scientific basis for a further understanding of the causes of type 2 diabetes complicated with peripheral neuropathy and the improvement of preventive strategies. The next step is to conduct further high-quality prospective cohort studies to validate this paper's findings.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Flowchart of the meta-analysis.
Fig 1. Flowchart of the meta-analysis.
Fig 2. Duration of diabetes and risk…
Fig 2. Duration of diabetes and risk of DPN.
The summary mean difference was calculated using a random-effects model. The mean difference and 95% CI for each study and the final combined results are displayed numerically on the left and graphically as a forest plot on the right. A and B are based on univariate analysis and multivariate analysis data, respectively. The sensitivity analysis results are shown in C.
Fig 3. Age and risk of DPN.
Fig 3. Age and risk of DPN.
The summary mean difference was calculated using a random-effects model. The mean difference and 95% CI for each study and the final combined results are displayed numerically on the left and graphically as a forest plot on the right. A and B are based on univariate analysis and multivariate analysis data for cross-sectional studies, respectively. C showed significant differences in age in the case-control studies. The sensitivity analysis results are shown in D.
Fig 4. HbA1c and risk of DPN.
Fig 4. HbA1c and risk of DPN.
The summary mean difference was calculated using a random-effects model. The mean difference and 95% CI for each study and the final combined results are displayed numerically on the left and graphically as a forest plot on the right. A and B are based on univariate analysis and multivariate analysis data, respectively. The sensitivity analysis results are shown in C.
Fig 5. DR and risk of DPN.
Fig 5. DR and risk of DPN.
The summary odds ratio was calculated using a fixed-effects model. The odds ratio and 95% CI for each study and the final combined results are displayed numerically on the left and graphically as a forest plot on the right. A and B are based on univariate analysis and multivariate analysis data, respectively.
Fig 6. Smoking and risk of DPN.
Fig 6. Smoking and risk of DPN.
The summary odds ratio was calculated using a random-effects model. The odds ratio and 95% CI for each study and the final combined results are displayed numerically on the left and graphically as a forest plot on the right. A and B are based on univariate analysis and multivariate analysis data, respectively.
Fig 7. BMI and risk of DPN.
Fig 7. BMI and risk of DPN.
The summary mean difference was calculated using a random-effects model. The mean difference and 95% CI for each study and the final combined results are displayed numerically on the left and graphically as a forest plot on the right. A and B are based on univariate analysis and multivariate analysis data, respectively. A subgroup analysis was conducted on the basis of ethnicity; the results are shown in C. The sensitivity analysis results are shown in D.
Fig 8. TC and risk of DPN.
Fig 8. TC and risk of DPN.
The summary mean difference was calculated using a random-effects model. The mean difference and 95% CI for each study and the final combined results are displayed numerically on the left and graphically as a forest plot on the right. A and B are based on univariate analysis and multivariate analysis data, respectively.
Fig 9. TG and risk of DPN.
Fig 9. TG and risk of DPN.
The summary mean difference was calculated using a random-effects model. The mean difference and 95% CI for each study and the final combined results are displayed numerically on the left and graphically as a forest plot on the right.

References

    1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice. 2018;138:271–81. 10.1016/j.diabres.2018.02.023 .
    1. Wang H, Hu R, Wu H, Yu M. [Progress in reporting incidence of type 2 diabetes]. Zhejiang Journal of Preventive Medicine. 2016;28(1):37–9,57.
    1. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clinic proceedings. 2006;81(4 Suppl):S3–11. .
    1. Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, et al. Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy. Clinical therapeutics. 2018;40(6):828–49. 10.1016/j.clinthera.2018.04.001 .
    1. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes care. 2010;33(10):2285–93. 10.2337/dc10-1303
    1. Mehra M, Merchant S, Gupta S, Potluri RC. Diabetic peripheral neuropathy: resource utilization and burden of illness. Journal of medical economics. 2014;17(9):637–45. 10.3111/13696998.2014.928639 .
    1. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes care. 2003;26(6):1790–5. .
    1. Barbosa AP, Medina JL, Ramos EP, Barros HP. Prevalence and risk factors of clinical diabetic polyneuropathy in a Portuguese primary health care population. Diabetes & metabolism. 2001;27(4 Pt 1):496–502. .
    1. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. The Lancet Neurology. 2012;11(6):521–34. 10.1016/S1474-4422(12)70065-0
    1. Won JC, Park TS. Recent Advances in Diagnostic Strategies for Diabetic Peripheral Neuropathy. Endocrinology and metabolism. 2016;31(2):230–8. 10.3803/EnM.2016.31.2.230
    1. Ning G. [Progress in the diagnosis of diabetic peripheral neuropathy]. Chinese Journal of Practical Internal Medicine. 2007;(7):487–9. 10.3969/j.issn.1005-2194.2007.07.003
    1. Al-Mahroos F, Al-Roomi K. Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study. Annals of Saudi medicine. 2007;27(1):25–31. 10.5144/0256-4947.2007.25 .
    1. Kiani J, Moghimbeigi A, Azizkhani H, Kosarifard S. The prevalence and associated risk factors of peripheral diabetic neuropathy in Hamedan, Iran. Archives of Iranian medicine. 2013;16(1):17–9. doi: 013161/AIM.006 .
    1. Nie C, Bao HP. [Analysis of the related risk factors of diabetic peripheral neuropathy]. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2012;26(6):467–9. .
    1. Rani PK, Raman R, Rachapalli SR, Pal SS, Kulothungan V, Sharma T. Prevalence and risk factors for severity of diabetic neuropathy in type 2 diabetes mellitus. Indian journal of medical sciences. 2010;64(2):51–7. 10.4103/0019-5359.94400 .
    1. Yang CP, Lin CC, Li CI, Liu CS, Lin WY, Hwang KL, et al. Cardiovascular Risk Factors Increase the Risks of Diabetic Peripheral Neuropathy in Patients With Type 2 Diabetes Mellitus: The Taiwan Diabetes Study. Medicine. 2015;94(42):e1783 10.1097/MD.0000000000001783
    1. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36(2):150–4. .
    1. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39(11):1377–84. .
    1. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38(11):1456–61. .
    1. Chen L, Zheng F, Li H. [A change of serum cystatin C in diabetic peripheral neuropathy in type 2 diabetic patients and its clinical significance]. Chinese Journal of Diabetes. 2014;22(8):700–3. 10.3969/j.issn.1006-6187.2014.08.007
    1. Wei W, Wang Z, Zhou l, Zhao S, Mao H. [Risk factors analysis of diabetic peripheral neuropathy in patients with type 2 diabetes]. Hainan Medical Journal. 2017;28(20):3379–81. 10.3969/j.issn.1003-6350.2017.20.035
    1. Chen X, Ma H, Chen Y, Ren Y, Chen Y, Zhong W, et al. [Risk factors analysis of diabetic peripheral neuropathy in patients with type 2 diabetes]. Chinese Journal of Diabetes. 2014;22(12):1057–9. 10.3969/j.issn.1006-6187.2014.12.001
    1. Wan H, Jiang X, Wang L, Yang L, Hua F. [Relationship between C-peptide level and peripheral neuropathy in patients with new diagnosed type 2 diabetes mellitus]. Chinese Journal of Diabetes. 2017;25(6):514–7. 10.3969/j.issn.1006-6187.2017.06.007
    1. He G, Sun C, Liu Y, Pan X, Wang G. [Characteristics of neurological damage and related factors in diabetic peripheral neuropathy]. Chinese Journal of Diabetes. 2014;22(2):118–21. 10.3969/j.issn.1006-6187.2014.02.007
    1. Chen X, Bi Y, Hu Y, Tong G, Zhu D. [Prevalence and risk factors of diabetic peripheral neuropathy]. Journal of Medical Postgraduates. 2011;24(10):1035–8. 10.3969/j.issn.1008-8199.2011.10.007
    1. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. Journal of pain and symptom management. 2005;30(4):374–85. 10.1016/j.jpainsymman.2005.04.009 .
    1. Hu YM, Zhao LH, Zhang XL, Cai HL, Huang HY, Xu F, et al. Association of glycaemic variability evaluated by continuous glucose monitoring with diabetic peripheral neuropathy in type 2 diabetic patients. Endocrine. 2018;60(2):292–300. 10.1007/s12020-018-1546-z .
    1. Morkrid K, Ali L, Hussain A. Risk factors and prevalence of diabetic peripheral neuropathy: A study of type 2 diabetic outpatients in Bangladesh. International journal of diabetes in developing countries. 2010;30(1):11–7. 10.4103/0973-3930.60004
    1. Shehab D, Al-Jarallah K, Mojiminiyi OA, Al Mohamedy H, Abdella NA. Does Vitamin D deficiency play a role in peripheral neuropathy in Type 2 diabetes? Diabetic medicine: a journal of the British Diabetic Association. 2012;29(1):43–9. 10.1111/j.1464-5491.2011.03510.x 22050401.
    1. Su JB, Zhao LH, Zhang XL, Cai HL, Huang HY, Xu F, et al. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients. Cardiovascular diabetology. 2018;17(1):47 10.1186/s12933-018-0693-0
    1. Juan Shen ML, Xiaoyan Liu, Xuling Xu, Hui Gong, Huifang Liu, Xiaowen Ma, Xiuli Zhao, Shimin Yan, Hong Yu, Fengling Chen. Relationship between postprandial C-peptide level and diabetic peripheral neuropathy in Chinese type 2 diabetes patients. Int J Clin Exp Pathol. 2016;9(9):9318–24.
    1. Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MH, Matthews DR. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetology & metabolic syndrome. 2012;4(1):21 10.1186/1758-5996-4-21
    1. Hu F, Yang J, Xie X, Ye J, Chen K. [Analysis of risk factors for patients with type 2 diabetes complicated with peripheral neuropathy]. Chinese Journal of General Practice. 2018;16(05):781–4.
    1. Xu F, Zhao LH, Su JB, Chen T, Wang XQ, Chen JF, et al. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetology & metabolic syndrome. 2014;6(1):139 10.1186/1758-5996-6-139
    1. Ybarra-Munoz J, Jurado-Campos J, Garcia-Gil M, Zabaleta-Del-Olmo E, Mir-Coll T, Zabalegui A, et al. Cardiovascular disease predicts diabetic peripheral polyneuropathy in subjects with type 2 diabetes: A 10-year prospective study. European journal of cardiovascular nursing: journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology. 2016;15(4):248–54. 10.1177/1474515114565215 .
    1. Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. Journal of diabetes investigation. 2014;5(6):714–21. 10.1111/jdi.12223
    1. Tesfaye S, Selvarajah D, Gandhi R, Greig M, Shillo P, Fang F, et al. Diabetic peripheral neuropathy may not be as its name suggests: evidence from magnetic resonance imaging. Pain. 2016;157 Suppl 1:S72–80. 10.1097/j.pain.0000000000000465 .
    1. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes research and clinical practice. 2000;47(2):123–8. .
    1. Cabezas-Cerrato J. The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups. Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS). Diabetologia. 1998;41(11):1263–9. .
    1. Liao Y. [Analysis of related influencing factors of HbA1c in patients with type 2 diabetes mellitus]. Contemporary Medicine. 2012;18(24):101–2. 10.3969/j.issn.1009-4393.2012.24.073
    1. Papanas N, Ziegler D. Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. The review of diabetic studies: RDS. 2015;12(1–2):48–62. 10.1900/RDS.2015.12.48
    1. Naqvi IH, Talib A, Akhter ST, Abdi SR, Rizvi SNZ, Ubaid M. Peripheral Neuropathy and Vasculopathy; Frequency and Associated Risk Factors in Newly Diagnosed Treatment Naive Type 2 Diabetes. Open Journal of Endocrine and Metabolic Diseases. 2018:125–36. 10.4236/ojemd.2018.85013
    1. Skalli S, Muller M, Pradines S, Halimi S, Wion-Barbot N. Vitamin D deficiency and peripheral diabetic neuropathy. European journal of internal medicine. 2012;23(2):e67–8. 10.1016/j.ejim.2011.11.008 .
    1. Ede O, Eyichukwu GO, Madu KA, Ogbonnaya IS, Okoro KA, Basil-Nwachuku C, et al. Evaluation of Peripheral Neuropathy in Diabetic Adults with and without Foot Ulcers in an African Population. Journal of Biosciences and Medicines. 2018:71–8. 10.4236/jbm.2018.612007

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다